106 related articles for article (PubMed ID: 16037656)
1. [Variability of efficacy measures in Alzheimer's disease].
Musicco M; Pettenati C; Caltagirone C
Ann Ist Super Sanita; 2005; 41(1):87-91. PubMed ID: 16037656
[TBL] [Abstract][Full Text] [Related]
2. Measuring cognitive change in Alzheimer's disease clinical drug trials.
Harrison JE
J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the therapeutic effects in individual patients with Alzheimer disease].
Richard E; Lemstra AW; Walstra GJ; van Gool WA
Ned Tijdschr Geneeskd; 2001 Feb; 145(8):340-5. PubMed ID: 11257811
[TBL] [Abstract][Full Text] [Related]
4. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations.
Conway EL
Clin Neuropharmacol; 1998; 21(1):8-17. PubMed ID: 9579280
[TBL] [Abstract][Full Text] [Related]
5. Galantamine for Alzheimer's disease and mild cognitive impairment.
Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
[No Abstract] [Full Text] [Related]
6. Donepezil in the treatment of patients with Alzheimer's disease.
Tsuno N
Expert Rev Neurother; 2009 May; 9(5):591-8. PubMed ID: 19402770
[TBL] [Abstract][Full Text] [Related]
7. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
[TBL] [Abstract][Full Text] [Related]
8. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
[TBL] [Abstract][Full Text] [Related]
9. Clinical inquiries. Does treatment with donepezil improve memory for patients with mild cognitive impairment?
Stiles MM; Martin S; Persons RK
J Fam Pract; 2006 May; 55(5):435-6. PubMed ID: 16670040
[No Abstract] [Full Text] [Related]
10. Memantine (Ebixa) in clinical practice - results of an observational study.
Calabrese P; Essner U; Forstl H
Dement Geriatr Cogn Disord; 2007; 24(2):111-7. PubMed ID: 17622714
[TBL] [Abstract][Full Text] [Related]
11. A neuropsychological test battery for use in Alzheimer disease clinical trials.
Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
[TBL] [Abstract][Full Text] [Related]
12. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
13. [Anti-Alzheimer drugs: ethical aspects of research and practice].
Berghmans RL
Tijdschr Gerontol Geriatr; 2000 Jun; 31(3):100-6. PubMed ID: 10900662
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
Bullock R
Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
16. Research design issues: antialuminum drug studies in Alzheimer's disease.
Shore D; Wyatt RJ
Clin Neuropharmacol; 1982 Dec; 5(4):337-43. PubMed ID: 7159877
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
18. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
20. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
